Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 diabetes
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 diabetes
Authors
Keywords
-
Journal
DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-10-23
DOI
10.1002/dmrr.3223
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
- (2019) Bernard Zinman et al. Lancet Diabetes & Endocrinology
- Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
- (2018) Dorrin Zarrin Khat et al. Current Diabetes Reports
- Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis
- (2018) Y.K. Cho et al. DIABETES & METABOLISM
- SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
- (2018) Michaël J.B. van Baar et al. DIABETES CARE
- Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
- (2018) Richard E. Pratley et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
- (2018) Dirk Müller-Wieland et al. DIABETES OBESITY & METABOLISM
- When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy
- (2018) Angelo Avogaro et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis
- (2018) Shanshan Wu et al. Expert Opinion On Drug Safety
- Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
- (2018) Se Hee Min et al. Scientific Reports
- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
- (2018) Bernhard Ludvik et al. Lancet Diabetes & Endocrinology
- The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes
- (2018) Kelly R. McHugh et al. CLINICAL CARDIOLOGY
- Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
- (2018) Serge A. Jabbour et al. DIABETES CARE
- Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial
- (2018) Kohei Kaku et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials
- (2016) Francisco J. Tinahones et al. DIABETES OBESITY & METABOLISM
- One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin
- (2016) S. Matthaei et al. DIABETES OBESITY & METABOLISM
- Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
- (2015) Andrew Lewin et al. DIABETES CARE
- Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
- (2015) Ralph A. DeFronzo et al. DIABETES CARE
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
- (2015) Feng Sun et al. Journal of Diabetes Research
- Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
- (2014) Julio Rosenstock et al. DIABETES CARE
- Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea
- (2011) Yoshimasa Aso et al. Translational Research
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Diabetes in Asia
- (2009) Ambady Ramachandran et al. LANCET
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started